24/09/2024
Gentlemen/ Members of the chamber
Greetings,
Asharqia Chamber extends its best regards to you, and informs you that it has received the letter of the Federation of Saudi Chambers No. (45507574) dated (14/3/1446 AH), which refers to what was received from the Public Health Authority "Weqaya" letter No. (023837-46-101) dated 02 Rabi` al-Awwal 1446 AH) regarding the Authority's study of preventive interventions for the following infectious diseases: Respiratory Syncytial Virus, Monkeypox, and Covid-19. Accordingly, it has recommended the following:
Subject: Recommendations related to long-acting antibodies (Niesevimab) for children:
First: Given the burden of respiratory syncytial virus (RSV) disease on children and its effects on the health system, the Authority recommends the use of the long-acting antibody (Niesevimab) to prevent complications of respiratory syncytial virus infection if available, according to the priority for the following categories:
First category: Children from the most vulnerable groups to the disease and those under 8 months of age who enter Or are born during their first RSV season and children from groups still considered at high risk of disease, aged 8 to 19 months, who are entering their second RSV season.
Group 2: Children under 8 months of age enter or are born during their first RSV season and who, if infected, have difficulty accessing health facilities that provide the necessary health services to treat RSV cases.
A brief guide for health practitioners on the management of monkeypox cases (MPAX):
(http://go.ac.sa/qzo)
|
Form for immediate reporting of a suspected case of monkeypox in the Kingdom of Saudi Arabia:
(http://go.ac.sa/vf0).
|
Sincerely
